Ignite Creation Date:
2024-05-06 @ 2:32 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02066974
Status:
UNKNOWN
Last Update Posted:
2015-02-05
First Post:
2014-02-18
Brief Title:
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
Sponsor:
China Medical University China
Organization:
China Medical University China
Study Overview
Official Title:
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
Status:
UNKNOWN
Status Verified Date:
2015-02
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC is a common cause of cancer mortality in Asia Most patients were presented with advanced disease Percutaneous ethanol injection radiofrequency ablation and transcatheter arterial chemoembolization TACE are not considered as a curative treatment and have achieved very limited success in eradicating large HCC or tumors causing portal vein thrombosis With the development of novel radiotherapy RT technique RT can be safely given to patients with larger tumor or portal vein thrombosis However RT could achieve a tumor response rate of approximately 50 Currently there was a paucity of studies regarding a quantitative biomarker to predict tumor response or forecast the outcome in advance To optimize the therapeutic index there is a need to seek effective biomarkers for personal medicine because pretreatment AFP is not always useful as a surrogate marker in some of the patients
The present study is to investigate whether circulating tumor cell genome in peripheral blood can be used to predict RT response in HCC We will use the blood sample from patients with locally advanced HCC receiving RT By using next generation sequencing We are going to explore the quantity and quality changes of DNAs and RNAs in the patients serum or plasma By this way genomic expression in peripheral blood may play a key role in determining the optimal therapeutic strategies for HCC patients by predicting tumor response to RT
The present study is to investigate whether circulating tumor cell genome in peripheral blood can be used to predict RT response in HCC We will use the blood sample from patients with locally advanced HCC receiving RT By using next generation sequencing We are going to explore the quantity and quality changes of DNAs and RNAs in the patients serum or plasma By this way genomic expression in peripheral blood may play a key role in determining the optimal therapeutic strategies for HCC patients by predicting tumor response to RT
Detailed Description:
Patients with hepatocellular carcinoma requiring radiotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None